Commercial Execution
Pathology Sales Strategy
Selling to pathology laboratories requires deep clinical and operational fluency. Standard enterprise software sales tactics fail because they ignore the regulatory constraints, reimbursement realities, and clinical risk tolerance unique to this market.
Who this service helps
- Commercial leaders at digital pathology and AI companies
- Sales executives entering the laboratory diagnostic space
- Founders scaling early commercial teams
- Marketing directors needing clinical message alignment
What the work can accomplish
- Sales playbooks that align with laboratory purchasing cycles and capital budget planning
- Clear differentiation messaging targeting lab directors, pathologists, and IT leadership
- Trained commercial teams capable of consultative clinical selling
- Shorter sales cycles through better qualification and stakeholder management
How we approach it
- We analyze your current pipeline to identify where deals stall or fail.
- We map the stakeholder consensus required to close in different lab settings (academic, independent, health system).
- We rebuild sales messaging to address clinical risk and operational ROI simultaneously.
- We train your team to speak the language of pathology, moving them from vendor to trusted advisor.
Experienced pathology leadership
David “DJ” Dalton, PhD, MBA brings more than 20 years of pathology industry experience spanning Labcorp, Paige AI, Lumea/Modella AI, digital pathology, laboratory operations, product strategy, commercialization, and executive leadership.
Last reviewed September 2026. About David Dalton
Frequently asked questions
Why are pathology sales cycles so long?
Pathology sales require consensus among clinical (pathologists), operational (lab directors), technical (IT), and financial stakeholders. Capital budget cycles and validation requirements naturally extend timelines. Proper qualification and multi-threading can accelerate this process.
How do we train software reps to sell to pathologists?
Reps must understand the diagnostic workflow, LIS integration, and the specific pressures on a pathologist's time. We train teams to focus on operational impact and clinical reliability rather than generic software features.
What is the biggest mistake vendors make in pathology sales?
Leading with 'efficiency' without understanding how pathologists are compensated. If a tool saves time but disrupts an established workflow or doesn't align with RVU generation, adoption will fail.